PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New dosing schedule for lymphoma drug shows promise in 66 patients
Disease control CompletedThis study tested the drug pembrolizumab (Keytruda) given every 6 weeks instead of every 3 weeks in 66 people whose Hodgkin's lymphoma or PMBCL had come back or not responded to prior treatment. The main goal was to see how many patients had their tumors shrink or disappear. The …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
633 PMBCL cases reviewed: what worked and what Didn't
Knowledge-focused CompletedThis study looked back at the medical records of 633 adults with primary mediastinal large B-cell lymphoma (PMBCL) treated between 2007 and 2019. The goal was to understand how well different treatments worked, how often the disease came back, and what side effects occurred. No n…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated May 17, 2026 03:09 UTC